Type 2 Diabetes Mellitus Clinical Trial
Official title:
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns in Obese Type 2 Diabetes Emirati Patients: a Randomized Controlled Clinical Trial.
Globally, type 2 diabetes mellitus (DM) and obesity are considered to be the fastest growing
disorders and their prevalence has increased dramatically over the last twenty years.
Recent studies have shown that about 19% of UAE population has been diagnosed with DM and 57%
of Emirati patients with type 2 DM are obese.
Optimal glycemic control and weight management involve comprehensive lifestyle approaches
including nutrition recommendations and adequate levels of physical activity.
However, recent views have suggested that there are other factors, such as sleep deprivation
and stress, contribute to development of type 2 DM.
Taking into account the previous findings, the present study was designed to investigate the
effects of a personalized intervention on weight and glycemic control in Emirati patients
with type 2 DM. The intervention involves assessment and modification of sleep patterns and
stress levels.
The present study is a randomized controlled trial which was conducted at Rashid Centre for
Diabetes and Research (RCDR) in Ajman which in one of the seven Emirates of the United Arab
Emirates (UAE). The study was approved by the research ethics committee of Al Qassimi
Clinical Research Centre, Al Qassimi Hospital (Ministry of Health, UAE).
The study population is comprised of Emirati individuals (n = 51) who attending RCDR diabetes
clinics in a quarterly basis (an initial visit and three follow-up visits per annum). The
participants were recruited from RCDR diabetes clinics and through different methods
including (i) direct contact (ii) distribution of informative flyers and (iii) phone calls
using Diamond, an electronic medical database of RCDR patients. The screening process
involved 110 Emirati patients with T2DM and 51 individuals were eligible to participate in
the present trial based on the following inclusion and exclusion criteria. The inclusion
criteria were (i) Age between 18-60 years (ii) Body Mass Index (BMI > 25 Kg/m2) and (iii)
T2DM. The exclusion criteria were (i) Age < 18 and > 60 years (ii) BMI < 25 Kg/m2) (iii) type
1 DM (iv) diagnosis of atrial fibrillation and/or atrial flutter and/or bundle branch block
and (v) heart transplantation.
The eligible participants were randomly allocated into an intervention group (n = 26) and or
into a control group (n = 25). Non-compliance was the main obstacle to maintain the same
number of the randomized participants in each group and 19% and 24 % of the participants in
the intervention and control group, respectively, did not attend the first visit.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 | |
Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|